Takeda Ventures
VC Fund
San Diego, United States
Takeda Ventures is a VC fund in San Diego focused on Biotechnology and Health Care. Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
- Total investments:
- 104
- Last investment:
- Lead investor:
- 18%
Last updated:
For AI agents: llms.txt
Industries Takeda Ventures invests in
Stages Takeda Ventures invests in
Countries Takeda Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Series A
- $10M–$58M
- Series B
- $20M–$130M
Investment Focus
Industry
- Biotechnology 63 (61%)
- Health Care 46 (44%)
- Therapeutics 27 (26%)
- Medical 20 (19%)
- Pharmaceutical 20 (19%)
Stage
- Series A 33 (32%)
- Series B 18 (17%)
- Funding Round 14 (13%)
- Series C 10 (10%)
- Seed 8 (8%)
Country
- United States 46 (44%)
- United Kingdom 8 (8%)
- Israel 4 (4%)
- Japan 3 (3%)
- Canada 2 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Michael Martin
Head of Takeda Ventures, Inc.
|
Head of Takeda Ventures, Inc. | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Accipiter Biosciences
|
Accipiter Biosciences is a biotechnology company. | $12.7M / Seed / Nov 06, 2025 | |
Integra Therapeutics
|
Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases. | $12.6M / Seed / Sep 08, 2025 | |
Harness Therapeutics
|
Transine Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. The company's pioneering technology is expected to offer an entirely unique mechanism of action for currentlyhard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. | Jan 27, 2025 | |
Degron Therapeutics
|
Degron Therapeutics is a leading platform company in discovery of molecular glue degraders for cancer treatment. | Series A / Jan 22, 2025 | |
Be Biopharma
|
Be Biopharma is developing B cells as medicines. | $92M / Series C / Jan 15, 2025 | |
|
Be Biopharma
|
Be Biopharma is developing B cells as medicines. | $82M / Venture - Series Unknown / Oct 22, 2024 | |
|
Be Biopharma
|
Be Biopharma is developing B cells as medicines. | Series C / Oct 22, 2024 | |
EvolveImmune Therapeutics
|
EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generatefirst-in-class treatments for unmet needs in oncology and autoimmune diseases. | $37.4M / Venture - Series Unknown / Nov 16, 2023 | |
Larkspur Biosciences
|
Larkspur's strategy focuses on the particular ways in which tumours hijack the immune system by developing precision immunotherapies for molecularly defined patient groups to overcome the bottlenecks that allow the tumour to subvert the immune system. | $35.5M / Series A / May 23, 2023 | |
OncoResponse
|
OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery. The company licensed the I-STAR™ platform, developed and validated by Theraclone Sciences of Seattle, tointerrogate the human memory B-cell repertoire of cancer patients who are considered “Elite Responders” to immunotherapy; as such, their own adaptive immune system responded to immunotherapy stimulation in a way that achieved curative or durable responses. From these Elite Responders, OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of fully human antibody derived therapeutics for the treatment of cancer. | $14M / May 18, 2023 | |
| See all 104 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Takeda Ventures invest in?
Takeda Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 104 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Takeda Ventures's check size?
Takeda Ventures typically joins rounds of $10M–$58M at Series A and $20M–$130M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Takeda Ventures participates in.
How do I contact Takeda Ventures?
Public channels for Takeda Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Takeda Ventures?
The team at Takeda Ventures includes Michael Martin (Head of Takeda Ventures, Inc.). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
